MARKET

NVCR

NVCR

Novocure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.13
+1.13
+1.51%
After Hours: 76.13 0 0.00% 16:00 08/13 EDT
OPEN
74.93
PREV CLOSE
75.00
HIGH
76.80
LOW
74.72
VOLUME
461.97K
TURNOVER
--
52 WEEK HIGH
98.84
52 WEEK LOW
53.40
MARKET CAP
7.70B
P/E (TTM)
25376.67
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVCR stock price target is 83.67 with a high estimate of 93.00 and a low estimate of 73.00.

EPS

NVCR News

More
Novocure Names CFO Wilco Groenhuysen COO; Names Ashley Cordova CFO
Benzinga · 18h ago
NovoCure (NVCR) Q2 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the NovoCure second-quarter 2020 earnings call. Good morning, everyone, and thank you for joining us to review NovoCure's second-quarter 2020 performance.
Motley Fool · 07/31 01:01
NovoCure shares are trading higher after the company reported better-than-expected Q2 sales results and EPS results up from last year.
Benzinga · 07/30 17:59
NovoCure EPS beats by $0.02, beats on revenue
NovoCure (NASDAQ:NVCR): Q2 GAAP EPS of $0.02 beats by $0.02. Revenue of $115.93M (+33.7% Y/Y) beats by $9.97M. There were 3,278 active patients at June 30,
seekingalpha · 07/30 15:03
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
NovoCure Q2 EPS $0.02 Up From $(0.01) YoY, Sales $115.92M Beat $106.03M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $115.92
Benzinga · 07/30 10:14
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update.
Business Wire · 07/30 10:00
NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/30 04:00

Industry

Medical Equipment, Supplies & Distribution
+0.61%
Healthcare Equipment & Supplies
+0.64%

Hot Stocks

Symbol
Price
%Change

About NVCR

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
More

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.